Oruka Therapeutics' Q4 Loss Narrows Beyond Expectations, Shares Hit 52-Week High
Summary
Oruka Therapeutics reported a fourth-quarter net loss of 45 cents per share, significantly narrower than the 64 cents per share loss analysts expected. This positive financial update was coupled with strong clinical trial progress, including the completion of enrollment for a key study and the initiation of a Phase 2 trial for a potential plaque psoriasis treatment. While the company's 10-K yesterday also noted clinical progress, this headline provides specific Q4 financial results and a more detailed update on pipeline milestones. The better-than-expected loss and continued pipeline momentum have propelled Oruka's shares up 22% to a new 52-week high, reflecting strong investor confidence. Traders will now be watching for the data readouts from the completed study in Q2 and the Phase 2 trial next year.
At the time of this announcement, ORKA was trading at $39.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $5.49 to $40.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.